Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

advanced or metastatic leiomyosarcoma who are inoperable are enrolled, aiming at the effectiveness and safety of temozolomide for injection combined with epirubicin as the first-line treatment for advanced

measurable disease
cancer
metastasis
cancer chemotherapy
neutrophil count
  • 0 views
  • 24 Mar, 2022
  • 1 location
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.

mammogram
carboplatin
erbb2
progesterone receptor
epirubicin
  • 0 views
  • 31 Jul, 2021
  • 7 locations
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus

soft tissue sarcoma
advanced soft tissue sarcoma
anlotinib
  • 0 views
  • 22 Mar, 2022
  • 3 locations
Epirubicin Oxaliplatin and Capecitabine or Docetaxel and Oxaliplatin in Treating Patients With Advanced Esophageal Cancer Gastroesophageal Junction Cancer or Stomach Cancer

RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, capecitabine, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells

combination chemotherapy
tumor cells
oxaliplatin
docetaxel
epirubicin
  • 136 views
  • 07 Nov, 2020
  • 3 locations
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

The study is being conducted to evaluate the efficacy, safety and tolerability of Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in Participants With Triple

  • 0 views
  • 26 Jan, 2021
  • 1 location
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

of dose-dense chemotherapy regimen (dd epirubicin/cyclophosphamide (EC) followed by dd paclitaxel (P)) and conventional chemotherapy (epirubicin/cyclophosphamide (EC) followed by docetaxel (T)) as

  • 4 views
  • 20 Aug, 2021
  • 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the

cyclophosphamide
rituximab
prednisone
bortezomib
  • 0 views
  • 23 Aug, 2021
  • 1 location
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy

  • 0 views
  • 22 Jan, 2021
  • 1 location
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer

This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab

  • 6 views
  • 23 Jan, 2021
  • 1 location
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

This is a single-arm, prospective, non-randomized, single-center, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib combined with epirubicin and

carcinoma
erbb2
inflammatory breast cancer
locally advanced breast cancer
advanced breast cancer
  • 0 views
  • 24 Mar, 2022
  • 1 location